Have you washed your hands? Then it’s time to start research!
As the spread of COVID-19 accelerates, and measures are enacted to help protect vulnerable people within society, it can be difficult to think about how we get ahead of this virus. A lot remains to be understood about its transmission and incubation, directly impacting the quality of the models being used to predict its spread. However, ‘necessity is the mother of invention’, and big challenges can help us learn new and more efficient ways of working. A good example of this is the R&D being performed across the globe to bring vaccines to market more rapidly while still ensuring patient safety. This is where Malvern Panalytical has a key role to play.
This webinar series will demonstrate why Malvern Panalytical’s physicochemical analysis solutions and expertise are applied to the development of stable, safe and effective vaccine formulations. We will focus on work by Sanofi-Pasteur, GSK and the University of Oxford, respectively developing rabies, respiratory syncytial virus (RSV), and meningitis vaccines. The use of Malvern Panalytical’s solutions by these organizations in reducing lead times by identifying the most suitable vaccine candidates, reducing cost by developing stable formulations at the preclinical stage, and optimizing shelf-life through predictive modelling, will be focused on.
- Focus on Vaccine Development – Candidate Selection
Prof. David Staunton (University of Oxford)
Applications of DSC to Structural Studies on Meningitis Vaccines by David Staunton of the University of Oxford
- Focus on Vaccine Development – Stability
Didier Clѐnet (Sanofi-Pasteur)
How Stable is Stable? Combining biophysical techniques and advanced kinetics to support formulation development and predict long-term stability of biologics
- Focus on Vaccine Development – Viral Vectors
Kirsty McManus (Allergan) and Jonathan Mehtala (Malvern Panalytical)
Strengthening the analytical workflow for rAAV viral vector development
- Focus on Vaccine Development – Storage
Dr. Matthew Scholfield (GSK)
Increasing the Efficiency of Vaccine Development Through Appropriate Selection of Storage Conditions at the Pre-Clinical Stage
- Focus on Vaccine Development – Viruses and VLPs, May 20th
Virus, Vaccine and VLP Characterisation with Nanoparticle Tracking Analysis (NTA)
Please bring your questions and join us to learn how Malvern Panalytical can support the excellent research being done in response to COVID-19.
- The nature of the Coronavirus illness means there is plenty of interest in respiratory tract administration – read here how we can add value to the development of respiratory delivery systems, including a practical example from Kiel University’s respiratory vaccine development work
- Many of the vaccines being developed are DNA-based, the purification of which is dependent on the understanding of plasmid morphology – read here how GSK is applying our solutions to DNA vaccine characterization
- Find out more about the importance of characterization to efficient viral vaccine development, particularly (and in light of the urgency with which vaccines are currently being developed) the value of rapid total viral concentration measurement
- Finally, adjuvant selection/development is a key part of the current drive for an effective vaccine – this example of adjuvant characterization from Nottingham University demonstrates the application of MP solutions to optimizing the performance of adjuvants